Thomas Björk

3.9k total citations · 2 hit papers
35 papers, 2.8k citations indexed

About

Thomas Björk is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Surgery. According to data from OpenAlex, Thomas Björk has authored 35 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 6 papers in Rheumatology and 5 papers in Surgery. Recurrent topics in Thomas Björk's work include Prostate Cancer Treatment and Research (25 papers), Prostate Cancer Diagnosis and Treatment (22 papers) and Hormonal and reproductive studies (5 papers). Thomas Björk is often cited by papers focused on Prostate Cancer Treatment and Research (25 papers), Prostate Cancer Diagnosis and Treatment (22 papers) and Hormonal and reproductive studies (5 papers). Thomas Björk collaborates with scholars based in Sweden, United States and Finland. Thomas Björk's co-authors include Hans Lilja, Per‐Anders Abrahamsson, Abraham T.�K. Cockett, David Ulmert, Anders Christensson, Andrew J. Vickers, Olle Nilsson, Marja‐Terttu Matikainen, Anders Bjartell and Peter T. Scardino and has published in prestigious journals such as Journal of Clinical Oncology, BMJ and The Journal of Urology.

In The Last Decade

Thomas Björk

32 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

2002 683 citations Danny Rischin, Malcolm Ranson et al. Journal of Clinical Oncology profile →
Serum Prostate Specific Antigen Complexed toα1-Antichymotrypsin as an Indicator of Prostate Cancer

1993 534 citations Anders Christensson, Thomas Björk et al. The Journal of Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Björk Sweden	22	2.0k	787	446	394	320	35	2.8k
Gerrit Draisma Netherlands	24	1.8k 0.9×	1.4k 1.8×	224 0.5×	147 0.4×	438 1.4×	39	3.2k
Alan R. Hay United States	5	1.6k 0.8×	221 0.3×	336 0.8×	534 1.4×	359 1.1×	8	2.2k
William J. Catalona United States	7	2.2k 1.1×	316 0.4×	361 0.8×	612 1.6×	427 1.3×	7	2.5k
Thierry Gil Belgium	22	2.1k 1.0×	1.1k 1.5×	668 1.5×	223 0.6×	841 2.6×	94	3.5k
Hiroshi Kitamura Japan	30	960 0.5×	751 1.0×	529 1.2×	157 0.4×	1.3k 4.0×	248	2.8k
Eli Rosenbaum Israel	34	972 0.5×	1.0k 1.3×	1.7k 3.9×	93 0.2×	615 1.9×	112	3.6k
Axel Semjonow Germany	35	2.6k 1.3×	797 1.0×	1.1k 2.4×	503 1.3×	672 2.1×	170	4.2k
Raymond S. Lance United States	24	1.4k 0.7×	647 0.8×	864 1.9×	195 0.5×	440 1.4×	51	2.6k
Danny Vesprini Canada	35	2.5k 1.2×	1.0k 1.3×	1.0k 2.3×	343 0.9×	828 2.6×	159	4.9k
Mary Ellen Taplin United States	16	4.2k 2.0×	1.6k 2.0×	924 2.1×	274 0.7×	530 1.7×	27	5.1k

Countries citing papers authored by Thomas Björk

Since Specialization

Citations

This map shows the geographic impact of Thomas Björk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Björk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Björk more than expected).

Fields of papers citing papers by Thomas Björk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Björk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Björk. The network helps show where Thomas Björk may publish in the future.

Co-authorship network of co-authors of Thomas Björk

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Björk. A scholar is included among the top collaborators of Thomas Björk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Björk. Thomas Björk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vickers, Andrew J., David Ulmert, Daniel D. Sjoberg, et al.. (2013). Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 346(apr15 5). f2023–f2023. 173 indexed citations

Björk, Thomas, Anders Szepessy, Raúl Tempone, & Georgios E. Zouraris. (2012). Monte Carlo Euler approximations of HJM term structure financial models. BIT Numerical Mathematics.

Vickers, Andrew J., Caroline Savage, Thomas Björk, et al.. (2011). 986 HOW SOON CAN WE IDENTIFY MEN AT HIGH RISK FOR PROSTATE CANCER DEATH? AN EARLY SURVEILLANCE STRATEGY FOR PROSTATE CANCER. The Journal of Urology. 185(4S). 1 indexed citations

Lilja, Hans, C. Savage, Axel Gerdtsson, et al.. (2011). Toward a rational strategy for prostate cancer screening based on long-term risk of prostate cancer metastases and death: Data from a large, unscreened, population-based cohort followed for up to 30 years.. Journal of Clinical Oncology. 29(15_suppl). 4512–4512. 2 indexed citations

Christensson, Anders, Thomas Björk, Angel M. Cronin, et al.. (2010). Intra‐individual short‐term variability of prostate‐specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer. British Journal of Urology. 107(11). 1769–1774. 8 indexed citations

Vickers, Andrew J., A. Cronin, Thomas Björk, et al.. (2010). Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. PubMed. 341(sep14 1). c4521–c4521. 151 indexed citations

Ulmert, David, Angel M. Cronin, Thomas Björk, et al.. (2008). Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study. BMC Medicine. 6(1). 6–6. 83 indexed citations

Vickers, Andrew J., David Ulmert, Angel M. Serio, et al.. (2007). The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically‐based screening strategy. International Journal of Cancer. 121(10). 2212–2217. 35 indexed citations

Bratt, Ola & Thomas Björk. (2007). [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].. PubMed. 104(46). 3460–4.

10.

Tyrrell, C., Peter Iversen, Teuvo L.J. Tammela, et al.. (2006). Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. British Journal of Urology. 98(3). 563–572. 27 indexed citations

11.

Bjartell, Anders, Thomas Björk, Virgil Gadaleanu, et al.. (2005). Immunohistochemical detection of cysteine‐rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. The Prostate. 66(6). 591–603. 38 indexed citations

12.

Ekberg, Henrik, et al.. (2004). RAPID ELIMINATION BY GLOMERULAR FILTRATION OF FREE PROSTATE SPECIFIC ANTIGEN AND HUMAN KALLIKREIN 2 AFTER RENAL TRANSPLANTATION. The Journal of Urology. 171(4). 1432–1435. 27 indexed citations

13.

LoRusso, Patricia, Roy S. Herbst, Danny Rischin, et al.. (2003). Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.. PubMed. 9(6). 2040–8. 40 indexed citations

14.

Björk, Thomas, et al.. (2001). Similar rates of exponential decrease in serum concentrations of free prostate‐specific antigen (PSA), PSA complexed to alpha‐1‐antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH‐analogues. The Prostate. 47(1). 14–20. 3 indexed citations

15.

Lilja, Hans, Alexander Haese, Thomas Björk, et al.. (1999). SIGNIFICANCE AND METABOLISM OF COMPLEXED AND NONCOMPLEXED PROSTATE SPECIFIC ANTIGEN FORMS, AND HUMAN GLANDULAR KALLIKREIN 2 IN CLINICALLY LOCALIZED PROSTATE CANCER BEFORE AND AFTER RADICAL PROSTATECTOMY. The Journal of Urology. 162(6). 2029–2035. 36 indexed citations

16.

Björk, Thomas, Bengt Ljungberg, Timo Piironen, et al.. (1998). Rapid Exponential Elimination of Free Prostate-Specific Antigen Contrasts the Slow, Capacity-Limited Elimination of PSA Complexed to Alpha1-Antichymotrypsin From Serum. Urology. 51(1). 57–62. 62 indexed citations

17.

Björk, Thomas, Timo Piironen, Kim Pettersson, et al.. (1996). Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology. 48(6). 882–888. 61 indexed citations

18.

Björk, Thomas, et al.. (1994). Alpha1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatc hyperplasia. Urology. 43(4). 427–434. 113 indexed citations

19.

Bjartell, Anders, et al.. (1993). Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology. 42(5). 502–510. 75 indexed citations

20.

Grabe, Magnus, Arne Forsgren, & Thomas Björk. (1986). Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection. European Journal of Clinical Microbiology & Infectious Diseases. 5(2). 211–212. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact